Laryngeal mask airway combined with visual bronchial blocker versus double-lumen tube for lung isolation in video-assisted thoracoscopic surgery: a protocol for a multicentre randomised controlled trial Authors: Yaodan Zhang, Tingting Li, Juan Wei, Rui Bao, Xin Lv, Jia-feng Wang, Jingxiang Wu Published: 2025 ABSTRACT AbstractIntroduction Postoperative sore throat and hoarseness are common complications following lung isolation with double-lumen tubes (DLTs) in video-assisted thoracoscopic surgery (VATS). Laryngeal mask airway (LMA) combined with a visual bronchial blocker (VBB) may reduce airway trauma while maintaining effective lung isolation.Methods and analysisThis is a prospective, randomised, controlled, single-blind, multicentre clinical trial conducted at three major thoracic surgery centres in Shanghai, China. A total of 270 patients aged ≥18 years scheduled for elective VATS anatomical lung resection will be randomly allocated 1:1 to either the VBB group (n=135) using LMA combined with VBB or the DLT group (n=135) using conventional DLT (see Consolidated Standards of Reporting Trials diagram). The primary outcome is the incidence of sore throat and hoarseness at 24 hours postoperatively. Secondary outcomes include sore throat and hoarseness at 1 and 48 hours, intraoperative device performance, lung collapse quality, intubation time, haemodynamic changes, emergence quality, device-related complications and hospital length of stay.Ethics and disseminationThe study protocol was approved by the Ethics Committee of Shanghai Chest Hospital (KS24042). Results will be disseminated through peer-reviewed publications and conference presentations.Trial registration numberClinicalTrials.gov (NCT07117539).Keywords: Adult anaesthesia, Thoracic surgery, Anaesthesia in oncology STRENGTHS AND LIMITATIONS OF THIS STUDY Multicentre randomised trial with central, stratified randomisation. Multicentre randomised trial with central, stratified randomisation. Blinded assessment of primary outcomes. Blinded assessment of primary outcomes. Standardised procedural protocols across sites. Standardised procedural protocols across sites. Comprehensive clinical endpoints. Comprehensive clinical endpoints. Blinding of the anaesthesiologists performing the interventions is not possible. Blinding of the anaesthesiologists performing the interventions is not possible. Introduction Video-assisted thoracoscopic surgery (VATS) has revolutionised thoracic surgery by offering reduced surgical trauma, improved visualisation and faster recovery compared with traditional open approaches.1 Effective lung isolation is essential for optimal surgical conditions in VATS procedures, with one-lung ventilation being the standard technique.2 Double-lumen tubes (DLTs) represent the most widely used method for lung isolation.3 However, their large external diameter and rigid construction are frequently associated with airway trauma and postoperative complications, including pharyngolaryngeal pain, hoarseness and oedema.4 5 Such complications can delay recovery and extend hospital stays.6 The combination of laryngeal mask airway (LMA) with bronchial blockers has emerged as a less traumatic alternative.7 LMAs avoid direct laryngoscopy and tracheal intubation, potentially reducing postoperative sore throat (POST) and hoarseness.6 7 Nonetheless, conventional bronchial blockers present challenges, such as difficult positioning, poor malleability and dependence on fibreoptic bronchoscopy (FOB).8 9 Recent evidence indicates that bronchial blockers may reduce airway injury and POST compared with DLTs.10 However, most studies have focused on traditional non-visual devices, which remain limited by their dependency on FOB.11 12 In parallel, technological advances have led to visual lung-isolation devices, such as video double-lumen endobronchial tubes, which incorporate real-time imaging to improve positioning and reduce the need for FOB.13 Building on these developments, a novel visual bronchial blocker (VBB; LTBLOCKER, Hangzhou Lantai, China) has been introduced, which integrates real-time visualisation with enhanced manoeuvrability. This device combines a disposable bronchoscope with an integrated blocking balloon, offering several potential advantages: independent, precise positioning without FOB, adjustable angulation for easier passage through vocal cords, real-time visualisation and continuous intraoperative monitoring. Despite these benefits, high-quality evidence comparing LMA combined with the VBB versus DLTs for lung isolation in VATS is lacking. This multicentre randomised controlled trial therefore aims to determine whether this combination reduces POST and hoarseness compared with DLTs while maintaining effective lung isolation. The results could influence clinical practice in thoracic anaesthesia and improve patient-centred outcomes. The clinical significance of this research extends beyond technical performance. POST and hoarseness may lead to prolonged discomfort, delayed oral intake, increased analgesic requirements and voice changes.7 For patients undergoing VATS—who anticipate quicker recovery—minimising such complications is essential. Furthermore, within the growing framework of enhanced recovery after surgery (ERAS) protocols in thoracic surgery, identifying lung isolation techniques that reduce morbidity while providing adequate surgical exposure is crucial for improving outcomes (figure 1). Consolidated Standards of Reporting Trials diagram. DLT, double-lumen tube; VBB, visual bronchial blocker. Objectives Primary objective To compare the incidence of sore throat and hoarseness at 24 hours postoperatively between LMA combined with VBB versus DLT for lung isolation in VATS. Secondary objectives To compare the incidence of sore throat and hoarseness at 1 and 48 hours postoperatively. To compare the incidence of sore throat and hoarseness at 1 and 48 hours postoperatively. To assess intraoperative device performance and complications. To assess intraoperative device performance and complications. To evaluate lung collapse quality and surgical conditions. To evaluate lung collapse quality and surgical conditions. To compare haemodynamic responses and emergence characteristics. To compare haemodynamic responses and emergence characteristics. To assess hospital length of stay and patient satisfaction. To assess hospital length of stay and patient satisfaction. Methods and analysis Study design This study will be conducted as a prospective, randomised, controlled, single-blind, multicentre clinical trial according to Consolidated Standards of Reporting Trials guidelines14 and Standard Protocol Items: Recommendations for Interventional Trials recommendations.15 Study setting The study will be conducted at three major thoracic surgery centres in Shanghai, China: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine (lead centre). Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine (lead centre). Shanghai Pulmonary Hospital, Tongji University School of Medicine. Shanghai Pulmonary Hospital, Tongji University School of Medicine. Shanghai Changhai Hospital, Naval Medical University. Shanghai Changhai Hospital, Naval Medical University. Eligibility criteria Inclusion criteria Age≥18 years. Age≥18 years. Scheduled for elective VATS anatomical lung resection under general anaesthesia. Scheduled for elective VATS anatomical lung resection under general anaesthesia. American Society of Anesthesiologists physical status I–III. American Society of Anesthesiologists physical status I–III. Body mass index 18.5–30.0 kg/m². Body mass index 18.5–30.0 kg/m². Written informed consent. Written informed consent. Exclusion criteria Anticipated difficult airway (Mallampati class IV, previous difficult intubation, airway abnormalities). Anticipated difficult airway (Mallampati class IV, previous difficult intubation, airway abnormalities). Gastro-oesophageal reflux disease or gastric retention. Gastro-oesophageal reflux disease or gastric retention. Active pulmonary infection or bleeding. Active pulmonary infection or bleeding. Severe pulmonary dysfunction (forced expiratory volume in one second <50% predicted). Severe pulmonary dysfunction (forced expiratory volume in one second <50% predicted). Previous lung surgery or planned bilateral lung surgery. Previous lung surgery or planned bilateral lung surgery. Cognitive impairment affecting outcome assessment. Cognitive impairment affecting outcome assessment. Chronic pharyngolaryngeal pain or voice abnormalities within 24 hours preoperatively. Chronic pharyngolaryngeal pain or voice abnormalities within 24 hours preoperatively. Abnormal bronchial anatomy on preoperative CT. Abnormal bronchial anatomy on preoperative CT. Pregnancy or breastfeeding. Pregnancy or breastfeeding. Participation in other clinical trials. Participation in other clinical trials. Randomisation and blinding Participants will be randomised 1:1 to either the VBB group or DLT group using computer-generated randomisation sequences stratified by centre. Block randomisation with varying block sizes (4, 6 and 8) will be employed to ensure balanced allocation within each centre. This study employs a single-blind design. Due to the distinct nature of the interventions, anaesthesiologists and surgical teams cannot be blinded to group allocation. However, patients and independent outcome assessors will remain blinded to treatment allocation. Interventions All airway management procedures will be performed by attending anaesthesiologists with at least 5 years of clinical experience in thoracic anaesthesia. Prior to the trial, each participating anaesthesiologist must complete a structured training programme conducted on airway manikins and successfully perform at least 10 supervised procedures using the LMA combined with the VBB technique. VBB group (intervention) The device (LTBLOCKER) integrates a micro-camera at its distal tip, providing a fixed forward view for real-time visualisation, thereby eliminating the need for a separate fibreoptic bronchoscope. The device (LTBLOCKER) integrates a micro-camera at its distal tip, providing a fixed forward view for real-time visualisation, thereby eliminating the need for a separate fibreoptic bronchoscope. A disposable LMA (model MLM; Zhejiang UE Medical, Hangzhou, China) will be used. Size selection is based on patient weight (≥70 kg: size 5, 50–70 kg: size 4 and <50 kg: size 3) per the manufacturer’s recommendation. The adequacy of the selected size was confirmed by achieving an oropharyngeal leak pressure >20 cm H₂O. A disposable LMA (model MLM; Zhejiang UE Medical, Hangzhou, China) will be used. Size selection is based on patient weight (≥70 kg: size 5, 50–70 kg: size 4 and <50 kg: size 3) per the manufacturer’s recommendation. The adequacy of the selected size was confirmed by achieving an oropharyngeal leak pressure >20 cm H₂O. Standard LMA insertion technique in supine position. Standard LMA insertion technique in supine position. Patient positioning in lateral decubitus for surgery. Patient positioning in lateral decubitus for surgery. VBB inserted through the LMA central channel. VBB inserted through the LMA central channel. Real-time visualisation guidance for optimal positioning. Real-time visualisation guidance for optimal positioning. Blocker advancement under direct vision to identify the carina. Blocker advancement under direct vision to identify the carina. Final positioning is achieved by advancing the device 15–20 mm beyond the carina into the target main bronchus, with visual verification of the right upper lobe orifice during right-sided placement. Final positioning is achieved by advancing the device 15–20 mm beyond the carina into the target main bronchus, with visual verification of the right upper lobe orifice during right-sided placement. Cuff inflation to achieve lung isolation. Cuff inflation to achieve lung isolation. Continuous monitoring throughout the procedure. Continuous monitoring throughout the procedure. If optimal lung isolation cannot be achieved after two attempts at placement or if a significant air leak persists, the technique will be considered a failure, and the airway will be managed at the attending anaesthesiologist’s discretion (eg, switching to a DLT). Such cases will be analysed on an intention-to-treat basis. If optimal lung isolation cannot be achieved after two attempts at placement or if a significant air leak persists, the technique will be considered a failure, and the airway will be managed at the attending anaesthesiologist’s discretion (eg, switching to a DLT). Such cases will be analysed on an intention-to-treat basis. DLT group (control) DLT selection and insertion Size selection based on patient gender and height16:Male: >180 cm (37F), 160–180 cm (35F) and <160 cm (32–35F).Female: >160 cm (35F), <155 cm (32F) and 155–160 cm (32–35F). Size selection based on patient gender and height16: Male: >180 cm (37F), 160–180 cm (35F) and <160 cm (32–35F). Male: >180 cm (37F), 160–180 cm (35F) and <160 cm (32–35F). Female: >160 cm (35F), <155 cm (32F) and 155–160 cm (32–35F). Female: >160 cm (35F), <155 cm (32F) and 155–160 cm (32–35F). Standard laryngoscopy and DLT insertion. Standard laryngoscopy and DLT insertion. Right-sided DLT may be selected for left-sided surgery when clinically indicated. Right-sided DLT may be selected for left-sided surgery when clinically indicated. FOB confirmation of positioning. FOB confirmation of positioning. Tracheal cuff pressure 25 cmH₂O, bronchial cuff pressure 30 cmH₂O. Tracheal cuff pressure 25 cmH₂O, bronchial cuff pressure 30 cmH₂O. Ventilation management (both groups) Volume-controlled ventilation based on ideal body weight. Volume-controlled ventilation based on ideal body weight. One-lung ventilation: tidal volume 4–6 mL/kg, respiratory rate 10–16/min. One-lung ventilation: tidal volume 4–6 mL/kg, respiratory rate 10–16/min. Two-lung ventilation: tidal volume 6–8 mL/kg. Two-lung ventilation: tidal volume 6–8 mL/kg. Positive end-expiratory pressure 4–6 cmH₂O (except patients with Chronic Obstructive Pulmonary Disease, COPD). In the event of a significant air leak with applied Positive End-Expiratory Pressure (PEEP), the PEEP level will be titrated downward to the minimum required to maintain adequate oxygenation (Pulse Oximetry Oxygen Saturation, SpO₂≥94%) or the LMA cuff position and pressure will be rechecked and adjusted. Positive end-expiratory pressure 4–6 cmH₂O (except patients with Chronic Obstructive Pulmonary Disease, COPD). In the event of a significant air leak with applied Positive End-Expiratory Pressure (PEEP), the PEEP level will be titrated downward to the minimum required to maintain adequate oxygenation (Pulse Oximetry Oxygen Saturation, SpO₂≥94%) or the LMA cuff position and pressure will be rechecked and adjusted. End-tidal CO₂ maintained at 35–45 mm Hg. End-tidal CO₂ maintained at 35–45 mm Hg. Outcomes These assessments will be conducted by a trained research nurse, who is blinded to the group allocation, at the patient’s bedside in the postanaesthesia care unit (1 hour) and the surgical ward. Primary outcome Incidence of sore throat and hoarseness at 24 hours postoperatively, defined as the presence of sore throat and/or hoarseness assessed using validated scoring systems17: Throat pain score: 0=no pain with swallowing, 1=pain only with swallowing, 2=continuous pain worsened by swallowing and 3=pain affecting eating or requiring analgesics. Hoarseness score: 0=no hoarseness, 1=patient-perceived hoarseness, 2=obvious hoarseness and 3=inability to speak. Secondary outcomes Sore throat and hoarseness incidence at 1 and 48 hours postoperatively. Sore throat and hoarseness incidence at 1 and 48 hours postoperatively. Intraoperative device displacement (lung re-expansion, airway pressure changes). Intraoperative device displacement (lung re-expansion, airway pressure changes). Intraoperative hypoxaemia (SpO₂<91%). Intraoperative hypoxaemia (SpO₂<91%). Lung collapse quality at 5, 10 and 20 min (incomplete/partial/complete collapse).18 Lung collapse quality at 5, 10 and 20 min (incomplete/partial/complete collapse).18 Intubation time (mouth opening to positioning completion). Intubation time (mouth opening to positioning completion). Haemodynamic changes (blood pressure variations during airway manipulation). Haemodynamic changes (blood pressure variations during airway manipulation). Emergence quality (coughing severity: none/single/continuous coughing). Emergence quality (coughing severity: none/single/continuous coughing). Device-related complications (malposition, air leak, repositioning requirements). Device-related complications (malposition, air leak, repositioning requirements). Hospital length of stay. Hospital length of stay. Participant timeline The participant timeline includes preoperative visit (eligibility screening, informed consent and baseline characteristics), allocation (randomisation), postallocation (intraoperative interventions and assessments) and follow-up (24-hour and 48-hour postoperative assessments and hospital discharge). The trial enrolment process is shown in figure 2. Diagram of the study process. DLT, double-lumen tube; VBB, visual bronchial blocker. Sample size calculation Sample size calculation was performed using PASS V.18.0 software, based on the primary endpoint of 24-hour sore throat and hoarseness incidence. Based on prior reports of 35–45% with DLT,6 19 we assumed a control (DLT) event rate of 30% and hypothesised a reduction to 15% with VBB (absolute difference 15%). With α=0.05 (two-sided) and power (1−β)=0.80, the required sample size is 121 patients per group. Allowing for a 10% dropout rate, the target enrolment is 135 per group (n=270 in total). Enrolment will be stratified by centre with permuted blocks, and each of the three centres will recruit 90 patients (45 per group). Statistical analysis All analyses will be performed using SPSS V.24.0 software following intention-to-treat principles. Continuous variables will be presented as means±SD or medians with IQRs, depending on distribution normality assessed by the Shapiro-Wilk test. Categorical variables will be presented as frequencies and percentages. Primary outcome analysis The incidence of POST and hoarseness at 24 hours will be compared between groups using the χ² test or Fisher’s exact test. Risk ratios and 95% CIs will be calculated. A post hoc exploratory multivariable logistic regression analysis will be performed only if the number of events is sufficient with prespecified covariates, including centre, age, sex and duration of surgery. Secondary outcome analyses Independent t-tests or Mann-Whitney U tests for continuous variables—χ² or Fisher’s exact tests for categorical variables—ordinal logistic regression for ordered categorical outcomes (pain/hoarseness scores). All statistical tests will be two-sided, with statistical significance set at p<0.05. Ethics and dissemination Ethics approval The study protocol was approved by the ethics committee of Shanghai Chest Hospital (approval number: KS24042, dated 15 December 2024). All participating centres have obtained local ethics approval. The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Consent Written informed consent will be obtained from all participants by qualified investigators at each participating centre. Dissemination Results will be disseminated through peer-reviewed publications in high-impact anaesthesia and thoracic surgery journals, presentations at national and international conferences, clinical practice guidelines and professional society recommendations. Trial status Current status: recruiting. Protocol version: V.2.1, dated 20 December 2024 Planned study start: 20 August 2025 Recruitment period: 20 August 2025–31 October 2025 Primary results expected: March 2026. Discussion This multicentre randomised controlled trial will provide crucial evidence regarding the comparative effectiveness and safety of LMA combined with VBB versus DLT for lung isolation in VATS. The study addresses a significant knowledge gap in thoracic anaesthesia practice and has the potential to transform clinical practice by providing evidence for less invasive airway management techniques. Expected outcomes and clinical implications Based on current evidence and theoretical considerations, we hypothesise that the VBB approach will demonstrate: Reduced POST and hoarseness incidence due to avoidance of direct laryngoscopy and tracheal intubation. Reduced POST and hoarseness incidence due to avoidance of direct laryngoscopy and tracheal intubation. Comparable lung isolation effectiveness with similar lung collapse quality and surgical conditions. Comparable lung isolation effectiveness with similar lung collapse quality and surgical conditions. Enhanced technical feasibility with reduced repositioning requirements and improved intraoperative monitoring. Enhanced technical feasibility with reduced repositioning requirements and improved intraoperative monitoring. Clinical and scientific impact The results will have significant implications for thoracic anaesthesia practice: Evidence-based guidelines for airway management technique selection in VATS. Evidence-based guidelines for airway management technique selection in VATS. Enhanced patient safety through reduced airway trauma and complications. Enhanced patient safety through reduced airway trauma and complications. Support for ERAS protocols in thoracic surgery through less invasive techniques. Support for ERAS protocols in thoracic surgery through less invasive techniques. Technology adoption framework for novel airway devices in clinical practice. Technology adoption framework for novel airway devices in clinical practice. Potential limitations We acknowledge several potential limitations: Provider blinding limitations due to the nature of interventions. Provider blinding limitations due to the nature of interventions. Learning curve effects for the novel VBB technique. Learning curve effects for the novel VBB technique. The visual blocker has a larger outer diameter due to its integrated camera, making it more bronchoscope-like in flexibility than a conventional blocker. Although its softer shaft and articulating tip may improve passage, the larger diameter (3.4 mm) traversing the glottis could still provide a mechanical stimulus affecting postoperative symptoms. Moreover,centre-specific variations existed in the application of clinical techniques for surgery and anaesthesia. The visual blocker has a larger outer diameter due to its integrated camera, making it more bronchoscope-like in flexibility than a conventional blocker. Although its softer shaft and articulating tip may improve passage, the larger diameter (3.4 mm) traversing the glottis could still provide a mechanical stimulus affecting postoperative symptoms. Moreover,centre-specific variations existed in the application of clinical techniques for surgery and anaesthesia. Generalisability may be limited to elective VATS procedures in tertiary care centres. The VBB is a relatively new device with limited adoption in routine practice; thus, the findings may have limited generalisability to settings without specific expertise or access to this technology. Generalisability may be limited to elective VATS procedures in tertiary care centres. The VBB is a relatively new device with limited adoption in routine practice; thus, the findings may have limited generalisability to settings without specific expertise or access to this technology. These limitations will be addressed through rigorous protocol standardisation, comprehensive staff training and appropriate statistical adjustments. Footnotes Funding: This study is supported by Jiren Charity Foundation (project no. JRH000032). The funding agency has no influence on study design, data collection, data analysis, data interpretation, manuscript writing or publication decisions. Prepub: Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-110539). Patient consent for publication: Consent obtained directly from patient(s). Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. References